No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 23.0x · 10Y median 23.0x · 59th percentile · as of Oct 6, 2026
Annual revenue · last 3 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:26:04.123Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CapsoVision, Inc. (CV) stock was $6.40 as of Oct 6, 2026, 10:22 AM EDT, down 2.81% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +37.4%
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Medical - Devices · Saratoga, CA
LATEST PRICE
$6.4
52-WEEK RANGE
$4.38 - $15.37
BETA
-2.46
% FROM 52W HIGH
-58.36%
MARKET CAP
$319.77M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
24.29
P/S RATIO
TTM
23.02
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.05
REVENUE TTM
$13.89M
GROSS MARGIN TTM
50.88%
NET PROFIT MARGIN TTM
-214.74%
REVENUE GROWTH TTM
TTM vs prior TTM
+10.99%
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
+37.37%
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.15
Revenue Est.
$3.74M
Last Quarter Results
EPS
$-0.15
vs Estimate
$-0.13
Revenue
$3.64M
vs Estimate
$3.81M
Consensus Rating
Based on 2 analysts
Average Price Target
$9.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Dec 2026 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Quarter ending Jun 2027 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CV | $319.77M | $6.40 | -2.81% | +37.37% | N/A | N/A | N/A |
| 2CABA | $320.40M | $1.97 | -5.53% | -14.69% | -28.71% | N/A | vs CV |
| 3CCCC | $321.75M | $2.91 | -2.68% | +31.55% | -41.77% | N/A | vs CV |
| 4MOBI | $313.37M | $9.43 | -1.72% | N/A | N/A | N/A | vs CV |
| 5CLPT | $330.19M | $11.01 | -4.43% | -57.75% | -7.65% | +6.57% | vs CV |
| 6LAB | $305.77M | $0.78 | +2.37% | -42.91% | -32.98% | -20.93% | vs CV |
+48.4% upside
Low
$9.00
Current
$6.40
High
$10.00
| $-0.12 |
| $-0.12 |
| $-0.12 |
| 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| FY 2027 | $-0.45 | $-0.45 | $-0.45 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $3.72M | $3.74M | $3.76M | 1 |
| Quarter ending Dec 2026 | $4.54M | $4.56M | $4.59M | 1 |
| Quarter ending Mar 2027 | $3.65M | $3.66M | $3.68M | 1 |
| Quarter ending Jun 2027 | $4.56M | $4.58M | $4.60M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $14.76M | $14.78M | $14.80M | 1 |
| FY 2027 | $19.25M | $19.28M | $19.31M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
